Literature DB >> 24468036

Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification.

Jong Lyul Lee1, Chang Sik Yu2, Misung Kim3, Seung-Mo Hong3, Seok-Byung Lim1, Jin Cheon Kim1.   

Abstract

BACKGROUND: Neuroendocrine carcinomas (NECs) arising in the large intestine are rare neoplasms with highly aggressive behavior. The aim of the study was to compare the 2000 and 2010 World Health Organization (WHO) classification of these colorectal NECs.
METHODS: We conducted a retrospective study of patients diagnosed with colorectal NECs according to the WHO 2000 classification who underwent surgery at the Asan Medical Center between May 2000 and December 2010. The data were reevaluated to assess their consistency with the WHO 2010 classification.
RESULTS: For 20 of the 34 patients (59%), the 2000 and 2010 WHO classifications yielded the same NEC diagnosis (NEC group), whereas for 14 of the 34 patients (41%), the WHO 2010 classification mandated a diagnosis of G1 or G2 neuroendocrine tumors (NETs) rather than NECs (G1/G2 NET group). The NEC group was older than the G1/G2 NET group (64 vs 55 years; P = .05). Tumor differentiation in the NEC group was poorer than in the G1/G2 NET group (percentage of poorly differentiated tumor, 70% vs 7%; P < .001). In both groups based on the 7th American Joint Committee on Cancer staging, most of the tumors were advanced at the time of diagnosis, reaching stage IIIB (6 NEC vs 10 NET) and stage IV (10 NEC vs 3 NET). The 5-year overall survival in the 2 groups was different (P = .02), but not the 5-year disease-free survival (P = .24).
CONCLUSION: These results indicate that the WHO 2010 classification of colorectal NEC is more accurate and has better prognostic value than the WHO 2000 classification.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24468036     DOI: 10.1016/j.surg.2013.11.012

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors.

Authors:  Beonghoon Sohn; Yoomin Kwon; Seung-Bum Ryoo; Inho Song; Yoon-Hye Kwon; Dong Woon Lee; Sang Hui Moon; Ji Won Park; Seung-Yong Jeong; Kyu Joo Park
Journal:  J Gastrointest Surg       Date:  2017-10-18       Impact factor: 3.452

2.  Endoscopic mucosal resection of early stage colon neuroendocrine carcinoma.

Authors:  Yasushi Yamasaki; Noriya Uedo; Ryu Ishihara; Yasuhiko Tomita
Journal:  BMJ Case Rep       Date:  2015-03-03

3.  Natural course of an untreated metastatic perirectal lymph node after the endoscopic resection of a rectal neuroendocrine tumor.

Authors:  Sang Hyung Kim; Dong-Hoon Yang; Jung Su Lee; Soyoung Park; Ho-Su Lee; Hyojeong Lee; Sang Hyoung Park; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Jin-Ho Kim; Chan Wook Kim; Jihun Kim
Journal:  Intest Res       Date:  2015-04-27

Review 4.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Authors:  Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge
Journal:  Diagnostics (Basel)       Date:  2015-04-08

5.  Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems.

Authors:  Chaoyong Shen; Yuan Yin; Huijiao Chen; Sumin Tang; Xiaonan Yin; Zongguang Zhou; Bo Zhang; Zhixin Chen
Journal:  Oncotarget       Date:  2017-03-28

6.  Rectal Neuroendocrine Tumor G1 with a Solitary Hepatic Metastatic Lesion.

Authors:  Kohei Nagata; Kazuto Tajiri; Seitarou Shimada; Takayuki Ando; Ayumu Hosokawa; Koshi Matsui; Joji Imura; Toshiro Sugiyama
Journal:  Intern Med       Date:  2017-02-01       Impact factor: 1.271

7.  The expression profile and clinical significance of circRNA0003906 in colorectal cancer.

Authors:  Fan Zhuo; Huashan Lin; Zhixin Chen; Zhijun Huang; Jiaping Hu
Journal:  Onco Targets Ther       Date:  2017-10-25       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.